Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

837 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Beyond Average: α-Particle Distribution and Dose Heterogeneity in Bone Metastatic Prostate Cancer.
Benabdallah N, Lu P, Abou DS, Zhang H, Ulmert D, Hobbs RF, Gay HA, Simons BW, Saeed MA, Rogers BE, Jha AK, Tai YC, Malone CD, Ippolito JE, Michalski J, Jennings JW, Baumann BC, Pachynski RK, Thorek DLJ. Benabdallah N, et al. Among authors: michalski j. J Nucl Med. 2024 Feb 1;65(2):245-251. doi: 10.2967/jnumed.123.266571. J Nucl Med. 2024. PMID: 38124163 Free PMC article.
Quantitative 68Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following 177Lu-PSMA-617 (VISION Trial).
Kuo PH, Morris MJ, Hesterman J, Kendi AT, Rahbar K, Wei XX, Fang B, Adra N, Garje R, Michalski JM, Chi K, de Bono J, Fizazi K, Krause B, Sartor O, Tagawa ST, Ghebremariam S, Brackman M, Wong CC, Catafau AM, Benson T, Armstrong AJ, Herrmann K. Kuo PH, et al. Among authors: michalski jm. Radiology. 2024 Aug;312(2):e233460. doi: 10.1148/radiol.233460. Radiology. 2024. PMID: 39162634 Clinical Trial.
Safety Analyses of the Phase 3 VISION Trial of [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer.
Chi KN, Armstrong AJ, Krause BJ, Herrmann K, Rahbar K, de Bono JS, Adra N, Garje R, Michalski JM, Kempel MM, Fizazi K, Morris MJ, Sartor O, Brackman M, DeSilvio M, Wilke C, Holder G, Tagawa ST. Chi KN, et al. Among authors: michalski jm. Eur Urol. 2024 Apr;85(4):382-391. doi: 10.1016/j.eururo.2023.12.004. Epub 2024 Jan 6. Eur Urol. 2024. PMID: 38185538 Free article. Clinical Trial.
Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy.
Evans JR, Zhao S, Daignault S, Sanda MG, Michalski J, Sandler HM, Kuban DA, Ciezki J, Kaplan ID, Zietman AL, Hembroff L, Feng FY, Suy S, Skolarus TA, McLaughlin PW, Wei JT, Dunn RL, Finkelstein SE, Mantz CA, Collins SP, Hamstra DA; PROSTQA Study Consortium. Evans JR, et al. Among authors: michalski j. Radiother Oncol. 2015 Aug;116(2):179-84. doi: 10.1016/j.radonc.2015.07.016. Epub 2015 Aug 11. Radiother Oncol. 2015. PMID: 26276528
Alpha emitter radium-223 and survival in metastatic prostate cancer.
Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franzén L, Coleman R, Vogelzang NJ, O'Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland ØS, Sartor O; ALSYMPCA Investigators. Parker C, et al. N Engl J Med. 2013 Jul 18;369(3):213-23. doi: 10.1056/NEJMoa1213755. N Engl J Med. 2013. PMID: 23863050 Free article. Clinical Trial.
NCCN Guidelines® Insights: Bladder Cancer, Version 3.2024.
Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Buyyounouski MK, Chan K, Chang SS, Chang P, Friedlander T, Greenberg RE, Guru KA, Herr HW, Hoffman-Censits J, Kaimakliotis H, Kishan AU, Kundu S, Lele SM, Mamtani R, Mian OY, Michalski J, Montgomery JS, Parikh M, Patterson A, Peyton C, Plimack ER, Preston MA, Richards K, Sexton WJ, Siefker-Radtke AO, Stewart T, Sundi D, Tollefson M, Tward J, Wright JL, Cassara CJ, Gurski LA. Flaig TW, et al. Among authors: michalski j. J Natl Compr Canc Netw. 2024 May;22(4):216-225. doi: 10.6004/jnccn.2024.0024. J Natl Compr Canc Netw. 2024. PMID: 38754471
Tight Junctions and Cancer: Targeting Claudin-1 and Claudin-4 in Thyroid Pathologies.
Borowczak J, Łaszczych D, Olejnik K, Michalski J, Gutowska A, Kula M, Bator A, Sekielska-Domanowska M, Makarewicz R, Marszałek A, Szylberg Ł, Bodnar M. Borowczak J, et al. Among authors: michalski j. Pharmaceuticals (Basel). 2024 Sep 30;17(10):1304. doi: 10.3390/ph17101304. Pharmaceuticals (Basel). 2024. PMID: 39458944 Free PMC article.
Postprostatectomy Radiotherapy Timing and Long-Term Health-Related Quality of Life.
Patel SA, Patil D, Smith J, Saigal CS, Litwin MS, Hu JC, Cooperberg MR, Carroll PR, Klein EA, Kibel AS, Andriole GL, Han M, Michalski JM, Wood DP, Hembroff LA, Spratt DE, Wei JT, Sandler HM, Hamstra DA, Pisters L, Kuban D, Regan MM, Wagner A, Crociani CM, Kaplan I, Sanda MG, Chang P; PROST-QA/RP2 Consortium. Patel SA, et al. Among authors: michalski jm. JAMA Netw Open. 2024 Oct 1;7(10):e2440747. doi: 10.1001/jamanetworkopen.2024.40747. JAMA Netw Open. 2024. PMID: 39446326 Free article.
Setting the Stage: Feasibility and Baseline Characteristics in the PARTIQoL Trial Comparing Proton Therapy Versus Intensity Modulated Radiation Therapy for Localized Prostate Cancer.
Wisdom AJ, Yeap BY, Michalski JM, Horick NK, Zietman AL, Christodouleas JP, Kamran SC, Parikh RR, Vapiwala N, Mihalcik S, Miyamoto DT, Zeng J, Gay HA, Pisansky TM, Mishra MV, Spratt DE, Mendenhall NP, Soffen EM, Bekelman JE, Efstathiou JA. Wisdom AJ, et al. Among authors: michalski jm. Int J Radiat Oncol Biol Phys. 2024 Sep 30:S0360-3016(24)03444-8. doi: 10.1016/j.ijrobp.2024.09.043. Online ahead of print. Int J Radiat Oncol Biol Phys. 2024. PMID: 39357788
837 results